Stock 6185 CANSINO BIOLOGICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

CanSino Biologics Inc. Stock

Equities

6185

CNE100003F01

Pharmaceuticals

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:16 2024-04-24 am EDT 		5-day change 1st Jan Change
18.06 HKD -1.85% Intraday chart for CanSino Biologics Inc. +5.12% -23.31%
Apr. 22 Cansino Bio Gets Nod for China Clinical Trials of Haemophilus Influenzae Vaccine MT
Apr. 22 Cansino Biologics Pneumococcal Vaccine's Phase I Trial Offers Positive Results MT

Financials

Sales 2024 * 858M 118M 927M Sales 2025 * 1.31B 181M 1.42B Capitalization 7.8B 1.08B 8.43B
Net income 2024 * -611M -84.33M -660M Net income 2025 * -409M -56.45M -442M EV / Sales 2024 * 8.84 x
Net cash position 2024 * 216M 29.77M 233M Net cash position 2025 * 870M 120M 940M EV / Sales 2025 * 5.27 x
P/E ratio 2024 *
-12 x
P/E ratio 2025 *
-117 x
Employees 1,494
Yield 2024 *
-
Yield 2025 *
-
Free-Float 39.3%
More Fundamentals * Assessed data

Chart CanSino Biologics Inc.

Dynamic Chart

Latest news about CanSino Biologics Inc.

Cansino Bio Gets Nod for China Clinical Trials of Haemophilus Influenzae Vaccine MT
Cansino Biologics Pneumococcal Vaccine's Phase I Trial Offers Positive Results MT
Cansino Biologics Begins Phase III Clinical Trials for Tetanus Drug MT
Cansino Biologics Inc. Announces Initiation of Phase III Clinical Trial and Completion of First Trial Patient Case for Absorbed Tetanus Vaccine CI
CanSino Biologics Sued by Brazilian Pharma Firm Belcher Over COVID-19 Vaccine Dispute MT
Cansino Biologics Inc. Announces Acceptance of Drug Registration Application for 13-Valent Pneumococcal Conjugate Vaccine CI
CanSino Biologics' Loss Widens in 2023, Misses EPS, Revenue Estimates; Shares Rise 4% MT
Cansino Biologics Inc. Announces Board and Committee Elections CI
CanSino Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
CanSino Biologics Deconsolidates CanSino SPH MT
CanSino Biologics' Loss to Widen in 2023; Shares Drop 5% MT
CanSino Biologics' 13-Valent Pneumococcal Vaccine Trial Shows Positive Results MT
Cansino Biologics Inc. Provides Earnings Guidance for Year Ended December 31, 2023 CI
CanSino Biologics Inc. Obtains the Final Report of Phase III Clinical Trial Of 13-Valent Pneumococcal Conjugate Vaccine CI
CanSino Biologics Enrols First Patient in Australia Clinical Trial of Polio Vaccine MT
More news

Analyst Recommendations on CanSino Biologics Inc.

Shares in Chinese Pharma Companies Decline Amid Drop in Vaccination Rates MT
Hong Kong Stocks Fall after Fed's Fourth Jumbo Rate Hike; Cansino Slumps 35% MT
UBS Adjusts CanSino Biologics' Price Target to HK$88 From HK$200, Keeps at Buy MT
UBS Adjusts CanSino Biologics’ Price Target to HK$200 From HK$202, Keeps at Buy MT
China stocks fall as virus worries, Fed rate hike bets weigh; Hong Kong up RE
More recommendations

Press releases CanSino Biologics Inc.

The Commercialization of Asia's First Meningococcal Conjugate Vaccine From CanSinoBIO Represents a Significant Breakthrough AQ
CanSino Biologics : CanSinoBIO Initiates Phase Ⅲ Clinical Trial of Group ACYW135 Meningococcal Conjugate Vaccine Menhycia® in Indonesia PU
CanSino Biologics : CanSinoBIO and SPIMACO Forge Strategic Partnership to Advance Accessibility of Cutting-Edge Vaccines PU
CanSino Biologics : CanSinoBIO Kicks-off the Polio VLP Vaccine Cooperation PU
CanSino Biologics : CanSinoBIO's Convidecia Air® Receives Approval in Indonesia PU
More press releases

News in other languages on CanSino Biologics Inc.

AstraZeneca comprará la china Gracell Biotechnologies en una operación de 1.200 millones de dólares
La china CanSino confía en que su vacuna COVID de ARNm sea tan buena como las de Moderna y Pfizer
Début de la migration du Nouvel an lunaire en Chine, hantée par le COVID-19
Cina : consentirà di usare test antigenici per confermare casi Covid-19
ANALYSEN DES TAGES von Dow Jones Newswires (06.12.2022)
More news

Quotes and Performance

1 day-1.85%
1 week+0.11%
Current month+13.44%
1 month+13.30%
3 months+1.46%
6 months-20.44%
Current year-23.31%
More quotes

Highs and lows

1 week
16.32
Extreme 16.32
18.80
1 month
15.34
Extreme 15.34
19.46
Current year
14.80
Extreme 14.8
23.60
1 year
14.80
Extreme 14.8
41.20
3 years
14.80
Extreme 14.8
437.00
5 years
14.80
Extreme 14.8
450.00
10 years
14.80
Extreme 14.8
450.00
More quotes

Managers and Directors - CanSino Biologics Inc.

Managers TitleAgeSince
Hui Hua Mao FOU
 Founder 62 09-01-12
Tao Zhu FOU
 Founder 51 09-01-12
Xue Feng Yu CEO
 Chief Executive Officer 60 09-01-12
Members of the board TitleAgeSince
Wing Yu Leung BRD
 Director/Board Member 53 15-08-31
Shou Bai Chao COO
 Chief Operating Officer 61 18-04-30
Dong Xu Qiu FOU
 Founder 64 09-01-12
More insiders

ETFs positioned on CanSino Biologics Inc.

Name Weight AuM 1st Jan change Investor Rating
LONCAR CHINA BIOPHARMA ETF - DISTRIBUTING - USD ETF Loncar China BioPharma ETF - Distributing - USD
0.75% 4 M€ -27.92%
KRANESHARES MSCI CHINA ESG LEADERS UCITS ETF ACC - USD ETF KraneShares MSCI China ESG Leaders UCITS ETF Acc - USD
0.11% 3 M€ -4.91% -
ICBCCS S&P CHINA 500 UCITS ETF CLASS B - USD ETF ICBCCS S&P China 500 UCITS ETF Class B - USD
0.01% 35 M€ -5.85% -
More ETFs positioned on CanSino Biologics Inc.

Quotes

Date Price Change Volume
24-04-24 18.06 -1.85% 783 800
24-04-23 18.4 +5.14% 2,333,400
24-04-22 17.5 +6.06% 1,273,900
24-04-19 16.5 -6.88% 1,980,500
24-04-18 17.72 -1.77% 557,200

Delayed Quote Hong Kong S.E., April 24, 2024 at 04:08 am EDT

More quotes

Company Profile

CanSino Biologics Inc is a clinical-stage vaccine company in China. The Company's products include Ad5-EBOV vaccine used for Ebola virus, MCV2 and MCV4 vaccines for meningococcus, PBPV vaccine used for pneumococcal and the recombinant novel coronavirus vaccine. Its products are mainly used in meningitis, diphtheria pertussis tetanus (DPT) and pneumonia.
Sector
Pharmaceuticals
Calendar
2024-04-24 - Q1 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for CanSino Biologics Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
17.01 CNY
Average target price
24.32 CNY
Spread / Average Target
+42.99%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
CANSINO BIOLOGICS INC. Stock CanSino Biologics Inc.
-23.31% 1.08B
CSL LIMITED Stock CSL Limited
-2.86% 87.37B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+4.08% 41.01B
BIOGEN INC. Stock Biogen Inc.
-25.35% 28.08B
UCB Stock UCB
+54.18% 24.72B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-4.52% 17.47B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-42.09% 11.69B
INCYTE CORPORATION Stock Incyte Corporation
-17.77% 11.6B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-12.10% 11.56B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+1.65% 8.44B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. 6185 Stock